Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Feb 13:4:64-75.
doi: 10.1016/j.trci.2018.01.003. eCollection 2018.

Measuring cognition and function in the preclinical stage of Alzheimer's disease

Sandra Weintraub  1   2 , Maria C Carrillo  3 , Sarah Tomaszewski Farias  4 , Terry E Goldberg  5 , James A Hendrix  3 , Judith Jaeger  6   7 , David S Knopman  8 , Jessica B Langbaum  9 , Denise C Park  10 , Michael T Ropacki  11 , Sietske A M Sikkes  12   13 , Kathleen A Welsh-Bohmer  14 , Lisa J Bain  15 , Robert Brashear  16 , Kumar Budur  17 , Ana Graf  18 , Ferenc Martenyi  19 , Marta Segardahl Storck  20 , Christopher Randolph  21   22
Affiliations
Review

Measuring cognition and function in the preclinical stage of Alzheimer's disease

Sandra Weintraub et al. Alzheimers Dement (N Y). .

Abstract

The Alzheimer's Association's Research Roundtable met in November 2016 to explore how best to measure changes in cognition and function in the preclinical stage of Alzheimer's disease. This review will cover the tools and instruments currently available to identify populations for prevention trials, and measure subtle disease progression in the earliest stages of Alzheimer's disease, and will include discussions of suitable cognitive, behavioral, functional, composite, and biological endpoints for prevention trials. Current prevention trials are reviewed including TOMMOROW, Alzheimer's Prevention Initiative Autosomal Dominant Alzheimer's Disease Trial, the Alzheimer's Prevention Initiative Generation Study, and the Anti-Amyloid Treatment in Asymptomatic Alzheimer's to compare current approaches and tools that are being developed.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Hypothetical interaction of amyloid and tau in preclinical AD. Abbreviations: AD, Alzheimer's disease; MTL, medial temporal lobe.
See this image and copyright information in PMC

References

    1. Park D.C., Lautenschlager G., Hedden T., Davidson N.S., Smith A.D., Smith P.K. Models of visuospatial and verbal memory across the adult life span. Psychol Aging. 2002;17:299–320. - PubMed
    1. Park D.C., Reuter-Lorenz P. The adaptive brain: aging and neurocognitive scaffolding. Annu Rev Psychol. 2009;60:173–196. - PMC - PubMed
    1. Mormino E.C., Kluth J.T., Madison C.M., Rabinovici G.D., Baker S.L., Miller B.L. Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. Brain. 2009;132(Pt 5):1310–1323. - PMC - PubMed
    1. Rodrigue K.M., Kennedy K.M., Devous M.D., Sr., Rieck J.R., Hebrank A.C., Diaz-Arrastia R. beta-Amyloid burden in healthy aging: regional distribution and cognitive consequences. Neurology. 2012;78:387–395. - PMC - PubMed
    1. Holtzman D.M., Herz J., Bu G. Apolipoprotein E and apolipoprotein E receptors: normal biology and roles in Alzheimer disease. Cold Spring Harb Perspect Med. 2012;2:a006312. - PMC - PubMed